2360-2361 / 2953
RT01 trial: 10-year follow-up:
No improvement in long-term survival with dose-
escalation (44% high risk)
Median follow-up:
10 years
Standard dose CFRT
64 Gy/32 fractions
(n=421)
Escalated-dose CFRT
74 Gy/37 fractions
(n=422)
HR (95% CI)
Deaths
120
119
Overall survival at 10
years
70%
70%
0.99 (0.77-1.28)
assumption of
proportional hazards
met: p=0.337
bPFS at 10 years
42%
54%
0.688 (0.56-0.84)
p<0.0001
bPFS events
224
172
Long-term HT
220 men overall: fewer men starting HT and
later in escalated-dose group
0.77 (0.59-1.00) p=0.05
20
bPFS, biochemical progression-free survival; CFRT, conformal radiotherapy; HR, hazard ratio; all comparisons expressed relative
to patients in standard group (i.e. HR <1
・
0 indicates decreased risk of event for escalated group); HT, hormone therapy
Dearnaley DP et al. ECCO/ESMO Sept 2011. Abstract 21LBA
In the longer-term perhaps 74 Gy is not a sufficient dose escalation
No mandated IGRT